<DOC>
	<DOCNO>NCT01160159</DOCNO>
	<brief_summary>Rationale : To analyse arterial state woman thrombophilia technique study micro arterial macrocirculation report still discuss increase risk cardio-vascular event woman . Primary objective : To measure endothelium dependent vasodilatation ( VDE ) control woman thrombophilia .</brief_summary>
	<brief_title>Arterial Microcirculation , Macrocirculation Thrombophilias</brief_title>
	<detailed_description>There several paper report increase risk arterial disease woman thrombophilia . However report remain controversial . In order gain insight issue propose study micro macrocirculation woman history venous thrombosis thrombophilia control match age . Design : It prospective open transversal trial . Management study : Two group 80 woman compare : healthy volunteer woman thrombophilia . Following inclusion consultation inform consent obtain inclusion criterion check , appointment arterial exploration give . These exploration measurement endothelium dependent vasodilatation ( EDV ) , capillar density , arterial fitness compliance retinogram . There follow-up visit.Benefits risk : measurement characterize arterial state patient thrombophilia include study.There risk perform technique . Principal criterion : measurement EDV . Secondary criterion : capillar density , arterial compliance stiffness retinogram .</detailed_description>
	<mesh_term>Thrombophilia</mesh_term>
	<criteria>healthy volunteer 1845 year old woman child bear age Without hormonal contraception hormone treatment since least 3 month Without arterial risk factor ( HTA , diabetes , dyslipemia , obesity , include smoke &gt; 5 cigaret ) Patient sign inform consent With thrombophilia : normal sample factor V II mutation Willing participate study Adherent health insurance Previous Clinical examination woman thrombophilia 1845 year old woman child bear age Without hormonal contraception hormone treatment since least 3 month Without arterial risk factor ( HTA , diabetes , dyslipemia , obesity , include smoke &gt; 5 cigaret ) Patient sign inform consent With thrombophilia : normal sample factor V II mutation Willing participate study Adherent health insurance Previous Clinical examination Women hormonal contraception stop less 3 month ago Women anticoagulant Arterial risk factor : HTA , diabetes , dyslipemia , obesity ( BMI &gt; 30 ) , include smoke &gt; 5 cigaret ) , metabolic syndrome , antiphospholipids/anticoagulant antibody , SLE History coronaropathy stroke Pregnant woman willing conceive Severe liver disease Women le 18y old 45y Severe liver diseases Patient willing sign inform consent Patient refusal participate Endometrial cancer Unexplored bleed Women willing participate include another trial Woman another thrombophilic disorder ( ATIII , protein C , S , history VTE without biological thrombophilic disorder . Women least one follow treatment stop 48h arterial investigation . Gynergen caffeine NOCERTONE® oxetorone SIBÉLIUM®flunarizine VIDORA®indoramine SANMIGRAN® 0,50 mg pizotifen woman propranolol AVLOCARDYL® 40 mg *AVLOCARDYL® LP 160 mg</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Venous thrombosis</keyword>
	<keyword>Women</keyword>
	<keyword>Vasodilatation endothelium-dependent</keyword>
	<keyword>IMT</keyword>
	<keyword>Arterial stiffness</keyword>
	<keyword>Arterial compliance</keyword>
	<keyword>Capillary density</keyword>
</DOC>